Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
Marilyn L. Slovak(City Of Hope National Medical Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Cheryl L. Willman(Mayo Clinic), Jacob M. Rowe(City Of Hope National Medical Center), David R. Head(Unknown), Anwar N. Mohamed(City Of Hope National Medical Center), Kenneth J. Kopecky(City Of Hope National Medical Center), Elizabeth Paietta(City Of Hope National Medical Center), Karl S. Theil(City Of Hope National Medical Center), David H. Harrington(City Of Hope National Medical Center), Peter A. Cassileth(City Of Hope National Medical Center), Stephen J. Forman(City Of Hope National Medical Center)
Cited by 1,580
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k